Breast Cancer Coverage from Every Angle

Ian E. Krop, MD, PhD, on Managing Toxicities of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer

Posted: Wednesday, February 5, 2020

Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses toxicities associated with trastuzumab deruxtecan, what seems to be most troublesome from patients’ perspective, and tips on how to manage the adverse effects.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.